Gain Therapeutics, Inc. (GANX)
| Market Cap | 46.79M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 4.87M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 14 |
| Last Price | $9.61 |
| Previous Close | $9.00 |
| Change ($) | 0.61 |
| Change (%) | 6.78% |
| Day's Open | 9.63 |
| Day's Range | 9.11 - 9.97 |
| Day's Volume | 27,521 |
| 52-Week Range | 8.75 - 17.93 |
Completed successful initial public offering and raised $46 million in gross proceeds --- Appointed four new independent board of directors to strengthen leadership team --- Signed a multi-target collab...
Compounds reverse the neurodegenerative process observed in a Parkinson's disease in vivo model
BETHESDA, Md., April 27, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ: GANX) (“Gain”) a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric bi...
Abstract highlighting Gain's STAR candidate for Parkinson's disease selected as one of the 10 Best Abstracts at the conference Abstract highlighting Gain's STAR candidate for Parkinson's disease selecte...
Collaboration to use Gain's proprietary Site-Directed Enzyme Enhancement Therapy (SEE-Tx™) computational platform technology to identify new and previously difficult-to-drug oncology targets
BETHESDA, Md., March 25, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain”) today announced the closing of its initial public offering of 3,636,364 shares of its common stock and full exercise of...
Last week was a busy one for the IPO market with 11 IPOs raising $3 billion, joined by 24 SPACs that brought another $8.4 billion to the table. Chinese IoT platform developer Tuya Inc (NYSE: TUYA) raise...
Gain Therapeutics, Inc. (“Gain”) today announced the pricing of its initial public offering of...
Gain Therapeutics, Inc. (“Gain”) today announced that it has launched the roadshow for its initial...
Gain Therapeutics, a preclinical biotech developing small molecule therapies for lysosomal storage disorders, filed on Friday with the SEC to raise up to $40 million in an initial public offering.
Gain Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.
About GANX
Gain Therapeutics is a development stage biotechnology company developing novel therapeutics to treat diseases caused by protein misfolding, with an initial focus on lysosomal storage disorders (“LSDs”), including rare genetic diseases and neurological disorders. We use our exclusively in-licensed proprietary platform, Site-Directed Enzyme Enhancement Therapy (“SEE-Tx”), to discover novel allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites and restore protein folding, potentially treatin... [Read more...]
| Industry Biotechnology | IPO Date Mar 18, 2021 |
| CEO Eric I. Richman | Employees 11 |
| Stock Exchange NASDAQ | Ticker Symbol GANX |
Financial Performance
In 2020, GANX's revenue was $28,881, a decrease of -30.07% compared to the previous year's $41,301. Losses were -$3.58 million, 63.1% more than in 2019.